These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14965150)

  • 1. Deficiencies of product labeling directions for the preparation of radiopharmaceuticals.
    Hung JC; Ponto JA; Gadient KR; Frie JA; Aksamit CM; Enquist CL; Carrels KE
    J Am Pharm Assoc (2003); 2004; 44(1):30-5. PubMed ID: 14965150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiencies in product labelling instructions and quality control directions for 99mTc radiopharmaceuticals.
    Buroni FE; Lodola L; Persico MG; Aprile C
    Nucl Med Commun; 2014 Feb; 35(2):197-204. PubMed ID: 24177040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current oral contraceptive use instructions: an analysis of patient package inserts.
    Williams-Deane M; Potter LS
    Fam Plann Perspect; 1992; 24(3):111-5. PubMed ID: 1628713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the stability of common radiopharmaceuticals compounded and utilized outside package insert guidelines.
    Weatherman KD; Augustine S; Christoff J; Galbraith W
    Int J Pharm Compd; 2013; 17(3):238-46. PubMed ID: 24046939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber.
    Marroum PJ; Gobburu J
    Clin Pharmacokinet; 2002; 41(3):161-9. PubMed ID: 11929317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription drug products that require patient package inserts; ampicillin and phenytoin--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28. PubMed ID: 10249520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current good manufacturing practices for PET drug products in the United States.
    Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ
    J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213
    [No Abstract]   [Full Text] [Related]  

  • 11. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 12. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1982 Sep; 47(173):39147-55. PubMed ID: 10258154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice.
    Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
    Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the compounding of positron emission tomography drugs.
    Hung JC
    Am J Health Syst Pharm; 2001 Jan; 58(2):134-9. PubMed ID: 11202536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the statements in the information on drug metabolizing enzyme in the package insert--the present regulation and its history in Japan, the U.S. and the U.K.
    Watanabe S; Misu T; Kurihara T; Suzuki S; Sakurada T; Satoh N; Ueda S
    Yakushigaku Zasshi; 2008; 43(2):175-80. PubMed ID: 19579828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical information in drug package inserts in India.
    Shivkar YM
    J Postgrad Med; 2009; 55(2):104-7. PubMed ID: 19550054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
    Pediatrics; 1996 Jul; 98(1):143-5. PubMed ID: 8668390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential elements of quality control.
    Boylan JC
    Am J Hosp Pharm; 1983 Nov; 40(11):1936-9. PubMed ID: 6650523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate use of oral drops: perception of health professionals and assessment of package insert information.
    Zaid AN; Al-Ramahi R; Abu Ghoush A
    Int J Clin Pharmacol Ther; 2010 Dec; 48(12):854-9. PubMed ID: 21084041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.